{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:47:47Z","timestamp":1792324067810,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007765","name":"Kansas State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016148","name":"Department of Pharmaceutical Chemistry, University of Kansas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016148","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejpb.2026.115025","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:05:46Z","timestamp":1771358746000},"page":"115025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Magnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0098-5749","authenticated-orcid":false,"given":"Moustafa M.","family":"Abdelaziz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8509-862X","authenticated-orcid":false,"given":"Maribel Espinoza","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8589-9304","authenticated-orcid":false,"given":"Chad","family":"Groer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5235-9677","authenticated-orcid":false,"given":"Huan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8773-0705","authenticated-orcid":false,"given":"Gerard","family":"Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Dimke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-6394","authenticated-orcid":false,"given":"Stephan","family":"Koepke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Bechtold-Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5082-8672","authenticated-orcid":false,"given":"Christian","family":"Sch\u00f6neich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-6138","authenticated-orcid":false,"given":"M.","family":"Laird Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2026.115025_b0005","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"Shepard","year":"2017","journal-title":"Clin. Med."},{"key":"10.1016\/j.ejpb.2026.115025_b0010","article-title":"2024 FDA approvals","author":"Mullard","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejpb.2026.115025_b0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","article-title":"Physicochemical stability of monoclonal antibodies: a review","volume":"109","author":"Le Basle","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11095-019-2689-1","article-title":"In vivo stability of therapeutic proteins","volume":"37","author":"Schuster","year":"2020","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115025_b0025","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2285277","article-title":"Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume","volume":"15","author":"Desai","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.ejpb.2026.115025_b0030","first-page":"45","article-title":"Optimization of therapeutic antibodies","volume":"4","author":"Wang","year":"2021","journal-title":"Antib. Ther."},{"key":"10.1016\/j.ejpb.2026.115025_b0035","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/07388551.2021.1874281","article-title":"Stability testing in monoclonal antibodies","volume":"41","author":"Kaur","year":"2021","journal-title":"Crit. Rev. Biotechnol."},{"key":"10.1016\/j.ejpb.2026.115025_b0040","first-page":"370","article-title":"Protein stability after administration: a physiologic consideration","volume":"112","author":"Schuster","year":"2023","journal-title":"JPharmSci"},{"key":"10.1016\/j.ejpb.2026.115025_b0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/antib14010002","article-title":"Rat as a predictive model for human clearance and bioavailability of monoclonal antibodies","volume":"14","author":"Robarge","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ejpb.2026.115025_bib301","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.biologicals.2016.06.005","article-title":"Determination of critical quality attributes for monoclonal antibodies using quality by design principles","volume":"44","author":"Alt","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.ejpb.2026.115025_bib302","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/btpr.1548","article-title":"Quality attributes of recombinant therapeutic proteins: An assessment of impact on safety and efficacy as part of a quality by design development approach","volume":"28","author":"Eon-Duval","year":"2012","journal-title":"Biotechnology Progress"},{"key":"10.1016\/j.ejpb.2026.115025_b0050","doi-asserted-by":"crossref","unstructured":"J. DeCaprio, T.O. Kohl, Immunoprecipitation, Cold Spring Harb Protoc 2020 (2020) pdb.top098509. Doi: 10.1101\/pdb.top098509.","DOI":"10.1101\/pdb.top098509"},{"key":"10.1016\/j.ejpb.2026.115025_b0055","doi-asserted-by":"crossref","unstructured":"I. \u0160afa\u0159\u0131\u0301k, M. \u0160afa\u0159\u0131\u0301kov\u00e1, Use of magnetic techniques for the isolation of cells, J. Chromatography B: Biomed. Sci. Appl. 722 (1999) 33\u201353. Doi: 10.1016\/S0378-4347(98)00338-7.","DOI":"10.1016\/S0378-4347(98)00338-7"},{"key":"10.1016\/j.ejpb.2026.115025_b0060","doi-asserted-by":"crossref","unstructured":"K.A. Van Schie, G.-J. Wolbink, T. Rispens, Cross-reactive and pre-existing antibodies to therapeutic antibodies\u2014Effects on treatment and immunogenicity, mAbs 7 (2015) 662\u2013671. Doi: 10.1080\/19420862.2015.1048411.","DOI":"10.1080\/19420862.2015.1048411"},{"key":"10.1016\/j.ejpb.2026.115025_b0065","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/rheumatology\/kem091","article-title":"On behalf of the research in active rheumatoid arthritis (ReAct) study group, effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice","volume":"46","author":"Bombardieri","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejpb.2026.115025_b0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/03946320140270S103","article-title":"Adalimumab in the treatment of immune-mediated diseases","volume":"27","author":"Lapadula","year":"2014","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115025_b0075","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1021\/acs.molpharmaceut.2c00840","article-title":"Visible light induces site-specific oxidative heavy chain fragmentation of a monoclonal antibody (IgG1) mediated by an iron(III)-containing histidine buffer","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115025_b0080","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/541471","article-title":"Hydrogen peroxide in inflammation: messenger, guide, and assassin","volume":"2012","author":"Wittmann","year":"2012","journal-title":"Adv. Hematol"},{"key":"10.1016\/j.ejpb.2026.115025_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279689","article-title":"A novel method for in silico assessment of Methionine oxidation risk in monoclonal antibodies: Improvement over the 2-shell model","volume":"17","author":"Tavella","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2026.115025_b0090","first-page":"S112","article-title":"Fenton reaction in vivo and in vitro","volume":"89","author":"Muranov","year":"2024","journal-title":"Possibilities and Limitations, Biochemistry"},{"key":"10.1016\/j.ejpb.2026.115025_b0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.xphs.2019.08.005","article-title":"Proteolysis and oxidation of therapeutic proteins after intradermal or subcutaneous administration","volume":"109","author":"Varkhede","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0100","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1021\/mp300563m","article-title":"Metal-catalyzed oxidation of protein methionine residues in human parathyroid hormone (1-34): formation of homocysteine and a novel methionine-dependent hydrolysis reaction","volume":"10","author":"Mozziconacci","year":"2013","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2026.115025_b0105","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.xphs.2017.09.022","article-title":"The use of a 2,2\u2019-azobis (2-amidinopropane) dihydrochloride stress model as an indicator of oxidation susceptibility for monoclonal antibodies","volume":"107","author":"Dion","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0110","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1039\/C5FO01550B","article-title":"Methionine sulfoxide profiling of milk proteins to assess the influence of lipids on protein oxidation in milk","volume":"7","author":"W\u00fcst","year":"2016","journal-title":"Food Funct."},{"key":"10.1016\/j.ejpb.2026.115025_b0115","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2122957","article-title":"Physicochemical and biological impact of metal-catalyzed oxidation of IgG1 monoclonal antibodies and antibody-drug conjugates via reactive oxygen species","volume":"14","author":"Glover","year":"2022","journal-title":"mAbs"},{"key":"10.1016\/j.ejpb.2026.115025_b0120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40259-016-0184-3","article-title":"Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab","volume":"30","author":"Liu","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejpb.2026.115025_b0125","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Therapeutics"},{"key":"10.1016\/j.ejpb.2026.115025_b0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11095-019-2696-2","article-title":"Methotrexate reduces the clearance of adalimumab by increasing the concentration of neonatal Fc receptor in tissues","volume":"36","author":"Deng","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115025_b0135","article-title":"Delanzomib, a novel proteasome inhibitor, combined with adalimumab drastically ameliorates collagen-induced arthritis in rats by improving and prolonging the anti-TNF-\u03b1 effect of adalimumab","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115025_b0140","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jpba.2009.01.030","article-title":"Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates","volume":"49","author":"Stubenrauch","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2026.115025_b0145","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/abio.1996.0320","article-title":"Applications of SYPRO orange and SYPRO red protein gel stains","volume":"239","author":"Steinberg","year":"1996","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejpb.2026.115025_b0150","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11095-013-1199-9","article-title":"Oxidation of therapeutic proteins and peptides: structural and biological consequences","volume":"31","author":"Torosantucci","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2026.115025_b0155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1042\/bj3500215","article-title":"Peroxidation of proteins before lipids in U937 cells exposed to peroxyl radicals","volume":"350","author":"Gieseg","year":"2000","journal-title":"Biochem. J"},{"key":"10.1016\/j.ejpb.2026.115025_b0160","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.xphs.2021.11.024","article-title":"Oxidation and deamidation of monoclonal antibody products: potential impact on stability, biological activity, and efficacy","volume":"111","author":"Gupta","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0165","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1002\/jps.22578","article-title":"Analysis of 2,2\u2019-azobis (2-amidinopropane) dihydrochloride degradation and hydrolysis in aqueous solutions","volume":"100","author":"Werber","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0170","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.molliq.2018.05.090","article-title":"Kinetic behavior of C.I. Reactive blue 182 towards oxidation with H2O2\/UV and H2O2\/NaOH systems","volume":"264","author":"Moissa","year":"2018","journal-title":"J. Mol. Liquids"},{"key":"10.1016\/j.ejpb.2026.115025_b0175","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.3390\/ijms22083952","article-title":"Monoclonal antibody aggregation associated with free radical induced oxidation","volume":"22","author":"Zheng","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0180","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1021\/acs.analchem.8b04768","article-title":"Selective tryptophan oxidation of monoclonal antibodies: oxidative stress and modeling prediction","volume":"91","author":"Pavon","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejpb.2026.115025_b0185","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1002\/jps.21746","article-title":"Methionine, tryptophan, and histidine oxidation in a model protein, PTH: mechanisms and stabilization","volume":"98","author":"Ji","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0190","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jchromb.2006.11.050","article-title":"Comparison of methionine oxidation in thermal stability and chemically stressed samples of a fully human monoclonal antibody","volume":"850","author":"Chumsae","year":"2007","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejpb.2026.115025_b0195","doi-asserted-by":"crossref","first-page":"7536","DOI":"10.1021\/ac501300m","article-title":"Detection of histidine oxidation in a monoclonal immunoglobulin gamma (IgG) 1 antibody","volume":"86","author":"Amano","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejpb.2026.115025_b0200","doi-asserted-by":"crossref","unstructured":"E. Folzer, K. Diepold, K. Bomans, C. Finkler, R. Schmidt, P. Bulau, J\u00f6r. Huwyler, H.-C. Mahler, A.V. Koulov, Selective oxidation of methionine and tryptophan residues in a therapeutic IgG1 molecule, J. Pharm. Sci. 104 (2015) 2824\u20132831. Doi: 10.1002\/jps.24509.","DOI":"10.1002\/jps.24509"},{"key":"10.1016\/j.ejpb.2026.115025_b0205","doi-asserted-by":"crossref","first-page":"9495","DOI":"10.1021\/acs.analchem.6b01958","article-title":"Understanding the impact of methionine oxidation on the biological functions of IgG1 antibodies using hydrogen\/deuterium exchange mass spectrometry","volume":"88","author":"Mo","year":"2016","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejpb.2026.115025_b0210","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1016\/j.xphs.2018.07.024","article-title":"Effect of peroxide- versus alkoxyl-induced chemical oxidation on the structure, stability, aggregation, and function of a therapeutic monoclonal antibody","volume":"107","author":"Shah","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0215","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1016\/j.xphs.2022.09.004","article-title":"Exploring the protein stabilizing capability of surfactants against agitation stress and the underlying mechanisms","volume":"111","author":"Zoeller","year":"2022","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0220","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.xphs.2019.10.051","article-title":"Unique impacts of methionine oxidation, tryptophan oxidation, and asparagine deamidation on antibody stability and aggregation","volume":"109","author":"Alam","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0225","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.chroma.2015.12.068","article-title":"Analysis of monoclonal antibody oxidation by simple mixed mode chromatography","volume":"1431","author":"Pavon","year":"2016","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejpb.2026.115025_b0230","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/10781552221137702","article-title":"Pharmacokinetic characterization, benefits and barriers of subcutaneous administration of monoclonal antibodies in oncology","volume":"29","author":"Hom\u0161ek","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ejpb.2026.115025_b0235","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40259-021-00470-1","article-title":"Treatment with SDZ-ADL, an adalimumab biosimilar, in patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis: results of patient-reported outcome measures from two phase III studies (ADMYRA and ADACCESS)","volume":"35","author":"Blauvelt","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejpb.2026.115025_b0240","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0924-8579(02)00022-5","article-title":"Animal model pharmacokinetics and pharmacodynamics: a critical review","volume":"19","author":"Andes","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ejpb.2026.115025_b0245","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bcp.13039","article-title":"Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira\u00ae in healthy subjects","volume":"82","author":"Hyland","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejpb.2026.115025_b0250","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/antib13030070","article-title":"A physiologically based pharmacokinetic model relates the subcutaneous bioavailability of monoclonal antibodies to the saturation of FcRn-mediated recycling in injection-site-draining lymph nodes","volume":"13","author":"Stader","year":"2024","journal-title":"Antibodies"},{"key":"10.1016\/j.ejpb.2026.115025_b0255","doi-asserted-by":"crossref","unstructured":"Y. Park, N. Kim, J. Choi, M.-H. Park, B. ill Lee, S.-H. Shin, J.-J. Byeon, Y.G. Shin, Qualification and application of a liquid chromatography-quadrupole time-of-flight mass spectrometric method for the determination of adalimumab in rat plasma, Pharmaceutics 10 (2018) 61. Doi: 10.3390\/pharmaceutics10020061.","DOI":"10.3390\/pharmaceutics10020061"},{"key":"10.1016\/j.ejpb.2026.115025_b0260","doi-asserted-by":"crossref","unstructured":"Y.N. Abdiche, Yeung ,Yik Andy, Chaparro-Riggers ,Javier, Barman ,Ishita, Strop ,Pavel, Chin ,Sherman Michael, Pham ,Amber, Bolton ,Gary, McDonough ,Dan, Lindquist ,Kevin, Pons ,Jaume, A. and Rajpal, The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity, mAbs 7 (2015) 331\u2013343. Doi: 10.1080\/19420862.2015.1008353.","DOI":"10.1080\/19420862.2015.1008353"},{"key":"10.1016\/j.ejpb.2026.115025_b0265","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0300-483X(03)00043-X","article-title":"Species differences in the structure and function of the immune system","volume":"188","author":"Haley","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.ejpb.2026.115025_b0270","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and opportunities for the subcutaneous delivery of therapeutic proteins","volume":"107","author":"Turner","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2026.115025_b0275","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217061","article-title":"Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates","volume":"14","author":"Walker","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejpb.2026.115025_b0280","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejpb.2026.115025_b0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00378","article-title":"Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: a phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)","volume":"21","author":"Howard","year":"2024","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ejpb.2026.115025_b0290","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin. Genitourin. Cancer"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641126000469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T16:51:37Z","timestamp":1776185497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641126000469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":60,"alternative-id":["S0939641126000469"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115025","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnetic immunoprecipitation assay for the isolation of adalimumab and degradation products in preclinical biological samples","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2026.115025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115025"}}